期刊文献+

甲氨蝶呤在1型糖尿病治疗中的应用研究进展 被引量:1

Methotrexate in type 1 diabetes mellitus: advances research
原文传递
导出
摘要 1型糖尿病(IDDM/T1DM)又称胰岛素依赖型糖尿病,是一种自身免疫性疾病。新近国际学术界还将其定义为重要自身免疫性疾病(IAID)中的一类。IDDM/T1DM最突出的病理生理特征是机体同时产生异常的自身体液和细胞免疫应答,最终导致胰岛β细胞损伤破坏,胰岛素分泌量绝对性减少。因此,针对IDDM/T1DM的传统主流治疗策略始终是采用胰岛素或胰岛素类似物的长期补充疗法。然而,长期使用常常会带来诸多的毒副作用尤其是低血糖反应或低血糖昏迷以及胰岛素抗性等。近年来针对其发病新机制所采用免疫抑制剂或免疫调节剂甲氨蝶呤(MTX)的临床应用备受关注,这将成为老药新用的又一重要范例。该文综述了MTX在治疗1型糖尿病方面的应用进展。 Type 1 diabetes mellitus( T1DM),also known as insulin dependent diabetes mellitus( IDDM),is classified as an autoimmune disease. Academia currently define it as one of the important autoimmune diseases( IAIDs). The most significant pathophysiological characteristics of T1 DM are the pathological humoral and cellular autoimmune response which results in damage to pancreatic β-cell and absolute reduction insulin. Thus,the mainstream traditional therapy for T1 DM has been to chronically replenish insulin or substitutes. Nevertheless,this approach may generate a number of side effects,especially hypoglycemia reaction,hypoglycemic coma and insulin resistance. In recent years,the clinical use of methotrexate( MTX) as an immunity inhibitor or regulator aiming at pathogenesis of T1 DM has received increasing attention and will become another significant case where an old drug is used for new purposes. The advances in research on MTX in T1 DM are discussed in this paper.
作者 运松 奚永志
出处 《军事医学》 CAS CSCD 北大核心 2015年第6期476-479,共4页 Military Medical Sciences
基金 国家高新技术研究发展计划资助项目(SQ2014SF02D00486)
关键词 Ⅰ型糖尿病 免疫调节剂 甲氨蝶呤 type 1 diabetes mellitus immunomodulator methotrexate
  • 相关文献

参考文献5

二级参考文献50

  • 1刘昌丽,余叶蓉,刘洪,张祥迅,赵桂芝.人白细胞抗原DQB1基因与1型糖尿病相关性研究[J].中华医学遗传学杂志,2004,21(4):368-371. 被引量:7
  • 2Seissler J, Scherbaum WA. Autoimmune diagnostics in diabetes mellitus. Clin Chem Lab Med, 2006, 44(2) :133 -137
  • 3韩加娥.GADAb、ICA及IAA联合检测对1型糖尿病的诊断意义.中国临床新医学,2006,6(2):163-164
  • 4Yang M,Charlton B, Gautam AM. Development of insulitis and diabetes in B cell - deficient NOD mice. J Autoimmun, 1997,10(3) : 257 - 260
  • 5Martin S, Wolf - Eichbaum D, Duinkerken G,et al. Development of type 1 diabetes despite severe hereditary B - cell deficiency. N Eng J Med, 2001,345(14) :1036 - 1040
  • 6Ramakrishna V, Jailkhani R. Evaluation of oxidative stress in Insulin Dependent Diabetes Mellitus (IDDM) patients. Diagn. Pathol, 2007, 2(1) :22
  • 7Kajimoto Y, Kaneto H. Role of oxidative stress in pancreatic beta - cell dysfunction. Ann NY Acad Sci, 2004,1011 :168 -176
  • 8Porras A, Zuluaga S, Valladares A, et al. Long - term treatment with insulin induces apoptosis in brown adipocyte:role of oxidative stress. Endocrinolongy, 2003, 144 ( 12 ) : 5390 - 5401
  • 9Cnop M, Welsh N, Jonas JC, et al. Mechanisms of pancreatic beta - cell death in typel and type 2 diabetes:many differences,few similarities. Diabeles,2005,54 ,Suppl 2 :S97 - S107
  • 10Wachlin G, Augsrein P, Schroder D, et al. IL - 1 beta, IFN - gamma and TNF - alpha increase vulnerability of pancreatic beta cells to autoimmune dcstruction,J Autoimmun,2003,20(4) :303 -312

共引文献76

同被引文献16

  • 1Hospira. Lable for methotrexate sodium [ EB/OL]. http:////umnv. accessdata, fda. gov/drugsatfda _ docs/label/2011/ O11719sl 171bl. pdf ,2011-10/2015-09-20.
  • 2DeAngelis LM. Brain tumors[J]. N Engl J Med,2001,344 (2) : 114-123.
  • 3DeAngelis LM. Chemotherapy for brain tumors--a new be- ginning[J]. N Engl J Meal,2005,352(10) : 1036-1038.
  • 4Ferreri AJ, Blay JY, Reni M ,et al. Prognostic scoring system for primary CNS lymphomas: the. International Extranodal Lymphoma Study Group experience[ J]. J Clin Oncol,2003, 21(2) : 266-272.
  • 5Ferreri A J, Reni M, Foppoli M, et al. High-dose eytarabine plus high-dose methotrexate versus high-dose methotrexate a- lone in patients with primary CNS lymphoma: a randomised phase 2 trial[J]. Lancet,2009,374(9700) : 1512-1520.
  • 6Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non- inferiority trial [ J ]. Lancet Oncology, 2010,11 ( 11 ) : 1036- 1047.
  • 7崔向丽,张国滨,张哲,任晓辉,许菲璠,林松.2012年NCCN颅内原发淋巴瘤诊疗指南解读[J].中国临床神经外科杂志,2013,18(8):469-471. 被引量:10
  • 8吴亮,徐傅能,陈璐,张丽娟,何林.大剂量甲氨蝶呤治疗急性淋巴细胞白血病及淋巴瘤的血药浓度监测与不良反应统计分析[J].实用医院临床杂志,2015,12(1):80-82. 被引量:13
  • 9牛卉,梅和坤,胡雪栋,梁蓓蓓,唐铭婧,汶柯,白艳,王瑾,张勇.红霉素长期小剂量超说明书用药的文献计量分析[J].中国临床药理学杂志,2015,31(3):223-226. 被引量:5
  • 10刘旭,柴栋,张云凯,蔡芸,王睿,王瑾.利奈唑胺PK/PD文献计量分析[J].中南药学,2015,13(1):102-105. 被引量:11

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部